We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Combined Urinary Procedure Used to Diagnosis Mucopolysaccharidoses

By LabMedica International staff writers
Posted on 18 Jan 2017
Print article
Image: The Shimadzu ultra violet–visible 1601 spectrophotometer (Photo courtesy of Shimadzu).
Image: The Shimadzu ultra violet–visible 1601 spectrophotometer (Photo courtesy of Shimadzu).
Mucopolysaccharidoses (MPS) are a group of rare genetic disorders of glycosaminoglycan (GAG) metabolism caused by the deficiency of one of the lysosomal enzymes required for GAG degradation. The diseases are characterized by the accumulation of undegraded glycosaminoglycans in lysosomes in multiple organs and by their excretion in high amounts in urine.

An early and accurate diagnosis of MPS is critical not only to permit disease-specific genetic counselling but also to guide appropriate supportive care and disease-specific therapy, when available. The first steps in the laboratory diagnosis of MPS suspected patients are based on the quantitative and qualitative analysis of urinary GAGs consisting of their quantitative as well as qualitative evaluation.

Scientists at the Marche Polytechnic University carried out retrospective study analyzing 2,154 normal urine samples and 210 samples from 73 patients affected by different types of Mucopolysaccharidoses. The glycosaminoglycans were quantified by a dimethylmethylene blue (DMB) method and size-fractionated by a modified one-dimensional electrophoresis method.

Untreated urine samples were analyzed for total GAG content using the DMB test and spectrophotometric measurements were recorded on a Shimadzu UV–visible 1601 spectrophotometer. Creatinine concentration was determined on 100 μL of urine by a Spotchem SP-4430 analyzer. Electrophoretic GAG characterization was performed using cellulose acetate membranes.

The investigators found that the combination of the two methods allowed identifying all the patients affected by the different types of Mucopolysaccharidosis with 100% sensitivity and specificity. The differences between the means displayed according to age values of the control samples and the corresponding values of the MPS patients are statistically significant in all groups with at least more than three samples. Out of 2,154 samples of normal subjects, an increased GAG concentration was found in 259 (12%) samples; however, none of them showed a pathological pattern at the electrophoresis.

The authors concluded that that the combined use of DMB test and electrophoresis allows the identification of all patients affected by MPS with 100% sensitivity and specificity. Moreover, this diagnostic approach provides useful information to proceed with further laboratory and diagnostic confirmatory tests, from enzyme assay to genetic analyses. The study was published in the January 2017 issue of the journal Clinica Chimica Acta.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.